- Home
- MCY vs PTGX Comparison
MCY vs PTGX Comparison
Compare MCY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCY
- PTGX
- Stock Information
- Founded
- MCY 1961
- PTGX 2006
- Country
- MCY United States
- PTGX United States
- Employees
- MCY N/A
- PTGX N/A
- Industry
- MCY Property-Casualty Insurers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- MCY Finance
- PTGX Health Care
- Exchange
- MCY Nasdaq
- PTGX Nasdaq
- Market Cap
- MCY 4.3B
- PTGX 3.7B
- IPO Year
- MCY N/A
- PTGX 2016
- Fundamental
- Price
- MCY $86.14
- PTGX $64.14
- Analyst Decision
- MCY Strong Buy
- PTGX Strong Buy
- Analyst Count
- MCY 1
- PTGX 8
- Target Price
- MCY $100.00
- PTGX $71.13
- AVG Volume (30 Days)
- MCY 241.4K
- PTGX 1.0M
- Earning Date
- MCY 10-28-2025
- PTGX 11-06-2025
- Dividend Yield
- MCY 1.46%
- PTGX N/A
- EPS Growth
- MCY 22.11
- PTGX N/A
- EPS
- MCY 7.04
- PTGX 0.80
- Revenue
- MCY $5,768,316,000.00
- PTGX $209,180,000.00
- Revenue This Year
- MCY $7.13
- PTGX N/A
- Revenue Next Year
- MCY $7.60
- PTGX $248.17
- P/E Ratio
- MCY $12.35
- PTGX $80.55
- Revenue Growth
- MCY 14.93
- PTGX N/A
- 52 Week Low
- MCY $44.19
- PTGX $33.31
- 52 Week High
- MCY $87.50
- PTGX $68.26
- Technical
- Relative Strength Index (RSI)
- MCY 72.48
- PTGX 56.23
- Support Level
- MCY $81.52
- PTGX $63.82
- Resistance Level
- MCY $85.96
- PTGX $68.26
- Average True Range (ATR)
- MCY 1.90
- PTGX 2.51
- MACD
- MCY 0.33
- PTGX -0.11
- Stochastic Oscillator
- MCY 85.73
- PTGX 55.94
About MCY Mercury General Corporation
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.